DEA Proposes Temporary Placement of 7-Hydroxymitragynine in Schedule I of Controlled Substances Act

The Drug Enforcement Administration (DEA) has issued a notice of intent to temporarily place 7-hydroxymitragynine, a substance found in kratom, above a specified threshold in Schedule I of the Controlled Substances Act. The DEA states that the substance poses an imminent hazard to public safety due to its high potential for abuse and lack of accepted medical use.

Context

7-hydroxymitragynine is a compound derived from kratom, a plant that has gained popularity for its stimulant and pain-relieving effects. The DEA's action follows increasing scrutiny of kratom and its components, as reports of adverse effects and addiction have surfaced. Currently, kratom is not classified as a controlled substance, leading to its widespread availability.

Why it matters

The DEA's proposal to classify 7-hydroxymitragynine as a Schedule I substance highlights concerns over public safety related to its potential for abuse. This classification could impact access to kratom products, which some users rely on for pain relief and other purposes. The decision reflects ongoing debates about the regulation of substances with psychoactive properties.

Implications

If 7-hydroxymitragynine is officially classified as a Schedule I substance, it could restrict access to kratom products, affecting users who rely on them for various health issues. This decision may also set a precedent for the regulation of other substances derived from natural sources. The classification could lead to increased law enforcement actions against kratom distributors and users.

What to watch

The DEA's notice will open a comment period for stakeholders, including healthcare professionals, users, and advocates, to voice their opinions. Observers will monitor public and legislative responses to the proposal, which could influence future regulatory decisions. Additionally, potential legal challenges may arise from the kratom community.